Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University, Sensyne Health, Evotec and OSI create new partnership called LAB10x to accelerate data-driven drug discovery powered by AI

Innovation Research

LAB10x aims to accelerate the commercialisation of the next generation of digital therapeutics and data-driven drug discovery from clinical artificial intelligence research and digital health innovations at Oxford University.

Sensyne Health, the British clinical artificial intelligence (AI) technology company, today announces that it has entered into a new strategic partnership with Evotec, a global drug discovery and development company, with Oxford University, Oxford University Innovation (OUI) and Oxford Sciences Innovation, the world’s largest IP investment company dedicated to a single university, aimed at accelerating the translation of research in the fields of clinical artificial intelligence and digital health at Oxford into breakthrough digital therapeutics, clinical AI algorithms and to accelerate data-driven drug discovery and development.

Read more (Oxford University Innovation website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

NCITA Publishes Comment Article in the British Journal of Cancer

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.